Clinical Study

J2g-Mc-Jzjb- A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Loxo-292 To Physicians Choice Of Cabozantinib Or Vandetanib In Patients With Progressive, Advanced, Kinase Inhibitor Naïve, Ret-Mutant Medullary Thyroid Cancer

Posted Date: Mar 4, 2020

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology, Thyroid Cancer
  • Type of Study: Drug

The goal of this study is to compare TFFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib.


To Be Eligible: Must Have Medullary Thyroid Cancer, Measurable Disease, Life Expectancy >3 Months, Ecog 0-2, No Active Cardiovascular Disease Or Severe Infection Or Illness, No Other Malignancy Within 2 Years


Thyroid Cancer, Medullary Thyroid, Head And Neck

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.